# Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

> **NCT04282187** · PHASE2 · RECRUITING · sponsor: **University of Washington** · enrollment: 25 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Essential Thrombocythemia
- Myelodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasm
- Myeloproliferative Neoplasm
- Myeloproliferative Neoplasm, Not Otherwise Specified
- Polycythemia Vera
- Primary Myelofibrosis
- Secondary Myelofibrosis

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Ruxolitinib
- **DRUG:** Fedratinib
- **OTHER:** Questionnaire Administration
- **DRUG:** Pacritinib
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT04282187
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-24
- **Primary completion:** 2026-11-11
- **Final completion:** 2026-11-11
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04282187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04282187, "Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04282187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*